HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer with significant therapeutic resistance.
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) targets cancer cells via death receptors (DR4/DR5), but clinical efficacy is limited.
• Hu antigen R (HuR) is a stress-response protein implicated in cancer progression and drug resistance.

Purpose of the Study:

• To identify novel mechanisms of TRAIL resistance in PDA.
• To investigate the role of HuR in mediating TRAIL resistance.
• To evaluate HuR inhibition as a strategy to enhance TRAIL sensitivity in PDA.

Main Methods:

• Overexpression and siRNA-mediated silencing of HuR in PDA cell lines.
• Assessment of TRAIL sensitivity and apoptosis induction.
• Analysis of HuR translocation, DR4 mRNA interaction, and cell surface receptor levels.
• Transcriptome analysis using NanoString to identify HuR-mediated pathways.
• Pharmacological inhibition of HuR using MS-444.

Main Results:

• HuR overexpression conferred TRAIL resistance, while HuR silencing sensitized PDA cells to TRAIL.
• TRAIL exposure induced HuR translocation from the nucleus to the cytoplasm.
• HuR directly interacted with the 3'-untranslated region of DR4 mRNA.
• HuR inhibition increased DR4/DR5 surface expression and enhanced TRAIL-induced apoptosis.
• HuR modulated global antiapoptotic gene expression in response to TRAIL.

Conclusions:

• HuR is a key regulator of TRAIL-induced apoptosis in PDA.
• Targeting HuR represents a promising strategy to overcome TRAIL resistance in pancreatic cancer.
• Re-evaluation of TRAIL-based therapeutics in combination with HuR inhibitors is warranted for PDA treatment.